Gilead Sciences, Inc.
industryDrug Manufacturers / General
exchangeNASDAQ Global Select
ipo dateJan 01, 1992
full time employees14,400
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon...Show More